Design Therapeutics, Inc. 8-K

What Happened
Design Therapeutics, Inc. filed an 8-K on June 11, 2026 reporting the outcomes of its 2026 Annual Meeting of Stockholders held June 9, 2026 (record date April 14, 2026). Stockholders elected Simeon George, M.D. as a Class II director to serve until the 2029 annual meeting, and ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The filing was signed by President and CEO Pratik Shah, Ph.D.

Key Details

• Shares outstanding and entitled to vote (record date April 14, 2026): 62,441,429.
• Director election (Simeon George, M.D.): 29,205,208 votes for; 7,608,724 votes withheld; 13,264,883 broker non‑votes.
• Ratification of independent auditor (Ernst & Young LLP): 50,077,708 votes for; 201 against; 906 abstentions.
• The company reported that fractional share voting was rounded down where applicable.

Why It Matters
This 8-K is a governance update: it confirms board continuity with the election of a Class II director and confirms the Audit Committee’s choice of Ernst & Young as auditor for 2026. For investors, these are routine but material corporate actions—director elections affect board composition and oversight, and auditor ratification affects financial statement oversight. The filing does not report any financial results, executive departures, or other operational changes.